Johnson & Johnson shares slip after jury orders it to pay $29 million in latest talcum cancer trial
Johnson & Johnson shares were down nearly 2 percent in premarket trading Thursday after it was ordered by a California jury to pay $29 million to a woman who alleged that asbestos in the company’s talcum-powder-based products.
It was the latest defeat for J&J, which is facing thousands of similar lawsuits. The company denies allegations that its talc causes cancer, saying numerous studies and tests by regulators worldwide have shown that its talc is safe and asbestos-free.
NewsOK highlights articles of interest from selected websites to increase the scope of commentary and coverage available to readers. Readers are linked back to the source of the content.